REPORTED: 2016/06/21 09:15

Test Name	Result	Flag	Reference Range	Lab
CBC With Differential/Platelet				
WBC	6.0		3.4-10.8 x10E3/uL	01
RBC	5.50		4.14-5.80 x10E6/uL	01
Hemoglobin	15.2		12.6-17.7 g/dL	01
Hematocrit	46.7		37.5-51.0 %	01
MCV	85		79-97 fL	01
MCH	27.6		26.6-33.0 pg	01
MCHC	32.5		31.5-35.7 g/dL	01
RDW	13.6		12.3-15.4 %	01
Platelets	252		150-379 x10E3/uL	01
Neutrophils	48		%	01
Lymphs	40		%	01
Monocytes	10		%	01
Eos	2		%	01
Basos	0		%	01
Neutrophils (Absolute)	2.9		1.4-7.0 x10E3/uL	01
Lymphs (Absolute)	2.4		0.7-3.1 x10E3/uL	01
Monocytes(Absolute)	0.6		0.1-0.9 x10E3/uL	01
Eos (Absolute)	0.1		0.0-0.4 x10E3/uL	01
Baso (Absolute)	0.0		0.0-0.2 x10E3/uL	01
Immature Granulocytes	0		%	01
Immature Grans (Abs)	0.0		0.0-0.1 x10E3/uL	01
Comp. Metabolic Panel (14)				
Glucose, Serum	88		65-99 mg/dL	01
BUN	17		6-20 mg/dL	01
Creatinine, Serum	1.06		0.76-1.27 mg/dL	01
eGFR If NonAfricn Am	90		>59 mL/min/1.73	01
eGFR If Africn Am	105		>59 mL/min/1.73	01
BUN/Creatinine Ratio	16		8-19	01
Sodium, Serum	138		134-144 mmol/L	01
Potassium, Serum	4.4		3.5-5.2 mmol/L	01
Chloride, Serum	97		97-108 mmol/L	01
Carbon Dioxide, Total	23		18-29 mmol/L	01
Calcium, Serum	9.4		8.7-10.2 mg/dL	01
Protein, Total, Serum	7.4		6.0-8.5 g/dL	01
Albumin, Serum	5.0		3.5-5.5 g/dL	01
Globulin, Total	2.4		1.5-4.5 g/dL	01
A/G Ratio	2.1		1.1-2.5	01
Bilirubin, Total	0.5		0.0-1.2 mg/dL	01
Alkaline Phosphatase, S	58		39-117 IU/L	01
AST (SGOT)	25		0-40 IU/L	01
ALT (SGPT)	26		0-44 IU/L	01
Urinalysis, Routine				
Specific Gravity	<=1.005	ABNORMAL	1.005-1.030	01
pH	7.5		5.0-7.5	01
Urine-Color	Yellow		Yellow	01
Appearance	Clear		Clear	01
WBC Esterase	Negative		Negative	01
Protein	Negative		Negative/Trace	01
Glucose	Negative		Negative	01
Ketones	Negative		Negative	01

Occult Blood	Negative		Negative	01
Bilirubin	Negative		Negative	01
Urobilinogen,Semi-Qn	0.2		0.2-1.0 mg/dL	01
Nitrite, Urine	Negative		Negative	01
Microscopic Examination	Comment			01
Microscopic not indicated and not performed.				
Lipid Panel				
Cholesterol, Total	203	HIGH	100-199 mg/dL	01
Triglycerides	90		0-149 mg/dL	01
HDL Cholesterol	43		>39 mg/dL	01
According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.				
VLDL Cholesterol Cal	18		5-40 mg/dL	01
LDL Cholesterol Calc	142	HIGH	0-99 mg/dL	01
Iron and TIBC				
Iron Bind.Cap.(TIBC)	466	HIGH	250-450 ug/dL	01
UIBC	339		111-343 ug/dL	01
Iron, Serum	127		38-169 ug/dL	01
Iron Saturation	27		15-55 %	01
Testosterone,Free and Total				
Testosterone, Serum	862		348-1197 ng/dL	01
Comment:	Comment			01
Adult male reference interval is based on a population of lean males up to 40 years old.				
Free Testosterone(Direct)	30.3	HIGH	8.7-25.1 pg/mL	02
Hemoglobin A1c				
Hemoglobin A1c	5.6		4.8-5.6 %	01

.

Pre-diabetes: 5.7 - 6.4
Diabetes: >6.4
Glycemic control for adults with diabetes: <7.0

Thyroxine (T4) Free, Direct, S				
T4,Free(Direct)	0.97		0.82-1.77 ng/dL	01
DHEA-Sulfate				
DHEA-Sulfate	453.9	HIGH	102.6-416.3 ug/dL	01
TSH				
TSH	3.220		0.450-4.500 uIU/mL	01
Luteinizing Hormone(LH), S				
LH	0.1	LOW	1.7-8.6 mIU/mL	01
FSH, Serum				
FSH	<0.2	LOW	1.5-12.4 mIU/mL	01
Prolactin				
Prolactin	6.2		4.0-15.2 ng/mL	01
Prostate-Specific Ag, Serum				
Prostate Specific Ag, Serum	0.6		0.0-4.0 ng/mL	01
Roche ECLIA methodology.				

.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.
Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

IGF-1				
Insulin-Like Growth Factor I	273	HIGH	88-246 ng/mL	02
C-Reactive Protein, Cardiac				
C-Reactive Protein, Cardiac	0.80		0.00-3.00 mg/L	01

Relative Risk for Future Cardiovascular Event

Low	<1.00
Average	1.00 - 3.00
High	>3.00

Estradiol, Sensitive				
Estradiol, Sensitive	14.7		8.0-35.0 pg/mL	02

This test was developed and its performance characteristics
determined by LabCorp. It has not been cleared by the Food and
Drug Administration.
Methodology: Liquid chromatography tandem mass spectrometry(LC/MS/MS)

GGT				
GGT	17		0-65 IU/L	01
Magnesium, Serum				
Magnesium, Serum	2.4	HIGH	1.6-2.3 mg/dL	01
Insulin				
Insulin	5.5		2.6-24.9 uIU/mL	01
Ferritin, Serum				
Ferritin, Serum	21	LOW	30-400 ng/mL	01
Triiodothyronine,Free,Serum				
Triiodothyronine,Free,Serum	3.3		2.0-4.4 pg/mL	01
Sex Horm Binding Glob, Serum				
Sex Horm Binding Glob, Serum	27.3		16.5-55.9 nmol/L	01

Performing Laboratory Information:

01: LabCorp Phoenix, 5005 S 40th Street Ste 1200, Phoenix AZ, phone: 800-788-9743
Medical Director: MD Brian Poirier
02: LabCorp Burlington, 1447 York Court, Burlington NC, phone: 800-762-4344
Medical Director: MD William F Hancock